This group focuses on the characterization of the DNA methylome and other epigenetic alterations in the CLL genome. The main objectives are: 

  • genomics 2To characterize the DNA methylome of samples from patients with CLL and purified B-cell samples obtained from age-matched healthy controls. 
  • To identify the genomic regions of differential DNA methylation between CLLs and controls, and assess whether the different genetic or cytogenetic groups show differential DNA methylation patterns.
  • To study the impact of aberrant epigenetic patterns on the CLL transcriptome.
  • To study whether DNA methylation aberrations correlate with clinical parameters.
  • To validate differentially-methylated genomic regions with clinical impact in an independent CLL series.